Clinical and experimental evidence suggest omicron variant of SARS-CoV-2 is inherently less pathogenic than delta variant independent of previous immunity

Eur J Med Res. 2023 Oct 11;28(1):421. doi: 10.1186/s40001-023-01373-3.

Abstract

Objectives: To study clinical disease outcomes in both human and animal models to understand the pathogenicity of omicron compared to the delta variant.

Methods: In this cross-sectional observational study, clinical outcomes of adults who tested positive at 2 testing centres in Delhi National Capital Region between January 2022 and March 2022 (omicron-infected; N = 2998) were compared to a similar geographical cohort (delta-infected; N = 3292). In addition, disease course and outcomes were studied in SARS-CoV-2-infected golden Syrian hamsters and K-18 humanized ACE2 transgenic mice.

Results: Omicron variant infection was associated with a milder clinical course [83% (95% CI 61, 94) reduced risk of severity compared against delta] adjusting for vaccination, age, sex, prior infection and occupational risk. This correlated with lower disease index and vir comparing omicron with other variants in animal models.

Conclusions: Infections caused by the omicron variant were milder compared to those caused by the delta variant independent of previous immunity.

Keywords: COVID-19; Omicron; SARS-CoV-2; hACE2 transgenic mice; hamster.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Animals
  • COVID-19*
  • Cricetinae
  • Cross-Sectional Studies
  • Disease Progression
  • Humans
  • Mice
  • SARS-CoV-2 / genetics

Supplementary concepts

  • SARS-CoV-2 variants